August 4 2016
Grafix(R) Manuscript Reporting Positive Outcomes of Multicenter Chronic Complex Wounds with Exposed Tendon and Bone Clinical Trial is Available Electronically in Peer-Reviewed Journal
COLUMBIA, Md. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that the manuscript from its multicenter prospective post-market clinical trial using Grafix was accepted for publication in the International Wound Journal , is now available online and will appear in an upcoming issue of the journal.
About the Trial (Protocol 310)
Patients between 18 and 85 years of age with confirmed type 1 or type 2 diabetes and with chronic complex diabetic foot wounds that extended through the dermis and into the subcutaneous tissue with evidence of exposed muscle, tendon, bone, and/or joint capsule were considered for this study. Ulcers had to be able to accommodate up to three 5 cm x 5 cm pieces of Grafix. Patients were excluded from the trial if the ulcer had any evidence of active infection at screening. Patients received treatment with Grafix weekly for up to 16 weeks. The primary endpoint measured 100% granulation of wound by 16 weeks as determined by the investigator. Secondary endpoints included complete wound closure rates, time to 100% granulation, number of applications, and percent wound area reduction at 4 weeks, 8 weeks, 12 weeks, and 16 weeks. 31 patients were enrolled, and 27 completed the study. The patient group had significant co-morbidity, with over 80% having hypertension, over 60% being current or former smokers, 55% having heart disease and 45% having had a previous partial amputation. The mean wound area was 14.6 cm2 with mean duration of 7.5 months, and 67.7% of patients failed advanced wound therapies prior to Grafix. For patients completing the protocol, the primary endpoint, 100% wound granulation by week 16, was met by 96.3% of patients in a mean of 6.8 weeks. Complete wound closure occurred in 59.3% (mean 9.1 weeks). Osiris Therapeutics partnered with CPC Clinical Research , an Academic Clinical Research Organization (CRO), who was responsible for data management and pharmacovigilance services. The protocol was submitted to clinicaltrials.gov (Reference # NCT02260609).
About Grafix®
